Mark Addleman

17 August 2023

No Comments

When an advanced lung cancer patient lost consciousness from acute hypoglycemia, doctors tried a treatment that proved to be a successful scientific breakthrough.

 

A 57-year-old advanced lung-cancer patient was brought to Hadassah in Jerusalem, unconscious from dangerously low blood sugar (hypoglycemia) due to a rare complication in which the tumour secretes a protein that diverts sugar into the muscle.

 

Doctors tried to raise his blood-sugar levels with conventional treatments without success. In fear for the patient’s life, Hadassah oncologists and endocrinologists tried something radical. And their resourcefulness led to a scientific breakthrough, as described in the New England Journal of Medicine.

 

“We started researching and looking for a solution for the patient until we came up with a drug called Alpelisib,” said Prof. Gil Leibowitz, Director of the Diabetes Unit at Hadassah. “Alpelisib is used to treat breast cancer. It works by inhibiting the pathway activated by the same protein that is responsible for the increased absorption of sugar in the muscle, and thus blood sugar levels rise,” he explained. “We knew we had nothing to lose. The patient’s condition was deteriorating, and we had to think out of the box and act immediately.”

 

A financial hurdle

 

Now they faced another hurdle as treatment with Alpelisib costs tens of thousands of dollars. It is not covered by national health insurance and the patient’s family could not afford it.

 

“When we first applied to the pharmaceutical company for compassionate treatment, we received a negative response due to the need for prior knowledge in the medical literature to use the drug in the context we wanted,” said Leibowitz. Undeterred, they obtained a dosage of the drug through the Haverim Le’Refuah (Friends for Health) national nonprofit organisation.

 

“Within a few hours of treatment, the patient’s measurements changed amazingly. We saw a gradual increase in blood sugar levels. On the second day, the patient no longer had hypoglycemia,” Leibowitz reported. The excellent results led to Alpelisib’s maker agreeing to fund the compassionate treatment for the patient for the rest of his life.

 

To understand the mechanism of how Alpelisib worked for the lung-cancer patient, Leibowitz and his team turned to Prof. Shulamit Levenberg, head of the Tissue and Stem Cell Engineering Laboratory at the Faculty of Biomedical Engineering at the Technion-Israel Institute of Technology.

 

Levenberg and doctoral student Hagit Shochat provided scientific proof of how Alpelisib affected the absorption of glucose within muscle cells, preventing hypoglycemia.

 

Leibowitz said many readers of the New England Journal of Medicine have contacted them about the breakthrough. “We hope this publication will lead to broader use of this drug for patients suffering from severe hypoglycemia and that the drug’s accessibility will increase for these patients,” he said.

 

Editors Notes

 

This is an excerpt from a story by Abigail Klein Leichman which was originally published in Israel21c – READ HERE

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe

Join our digital newsletter to stay in touch with the latest news from Hadassah UK